Merck reported a decline in worldwide sales and lowered its full-year guidance due to significant patent expirations and unfavorable foreign exchange impacts. While the company announced a substantial share repurchase program and highlighted growth in certain segments, the immediate sentiment is overshadowed by the short-term financial challenges.

[-1]